Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.

Industry News Archive

  • CMS Releases CY 2021 OPPS and PFS Proposed Rules

    On August 4, 2020, the Centers for Medicare & Medicaid Reimbursement (CMS) issued the calendar year (CY) 2021 Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Payment Proposed Rule (CMS-1736-P). ACCC and council are reviewing these proposed rules and will be providing comments.

    Until this analysis is complete, read the proposed OPPS rule and the proposed PFS rule. Then register for ACCC’s August 14 webcast on The 2021 Proposed PFS and OPPS Rules: Practical Implications and Considerations to gain insight into how these proposed rules will affect your cancer program.


    Posted 8/6/2020



  • FDA Approves Tafasitamab-cxix + Lenalidomide for R/R DLBCL

    On July 31, 2020 MorphoSys and Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.

    Read corporate press release.

    Read FDA announcement.

    Posted 8/3/20



  • FDA Approves Inqovi Tablets for Adults with Intermediate and High-Risk Myelodysplastic Syndromes

    On July 7, 2020, the U.S. Food and Drug Administration (FDA) and Health Canada have approved decitabine and cedazuridine (Inqovi, Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd.) tablets for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).

    Approval was based on data from the ASCERTAIN phase 3 study and supporting phase 1 and 2 clinical studies. The ASCERTAIN phase 3 study evaluated the five-day, decitabine exposure equivalence between oral Inqovi® and intravenous decitabine. The safety and efficacy of Inqovi® was also assessed in the clinical studies.

    Read corporate announcement

    Posted 7/17/2020



  • FDA Approves Keytruda for Patients with Unresectable or Metastatic MSI-H or dMMR CRC

    On June 29, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck & Co.) for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

    MSI-H/dMMR testing is required prior to initiating treatment with Keytruda in these patients. For the MSI-H/dMMR indication, select patients for treatment with Keytruda as a single agent based on MSI-H/dMMR status in tumor specimens. An FDA-approved test for the detection of MSI-H or dMMR is not currently available.

    Read prescribing information and medication guide

    Posted 7/17/2020



  • FDA Approves Pembrolizumab for Patients with Recurrent or Metastatic cSCC

    On June 24, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck & Co.) injection 100 mg for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. 

    Read FDA announcement and prescribing information

     

    Posted 7/14/2020



  • FDA Approves Phesgo™ Injection for Subcutaneous Use

    On June 29, 2020, the U.S. Food and Drug Administration (FDA) approved pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo, Genentech) injection, for subcutaneous use.

    Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for:

      Phesgo™ is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

      Read corporate announcement.

      Billing and coding sheet.

      Prescribing information.

      Posted 7/14/2020



    • Enhertu Receives Permanent J-Code

      Effective July 1, 2020, ENHERTU® (fam-trastuzumab deruxtecan-nxki) has a permanent j-code: J9358. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting.

      For full prescribing information, click here

      Posted 7/7/20



    • Update: COVID-19 Emergency Food Assistance Grant Amount Change

      Due to increasing demand for the program’s financial assistance, the individual grant award amount has been changed to $300 effective immediately. This adjustment will allow thousands of additional patients to receive meaningful financial support for nutritional needs while maximizing the reach of available funding as the number of people impacting by COVID 19 continues to accelerate.

      To date, the COVID-19 Emergency Food Assistance Program has helped more than 13,000 patients, including 1,000 emergency food deliveries made and over 12,000 financial assistance grants being provided to patients in all 50 states.  

      This innovative program is a collaboration between Team Rubicon (TR) and Patient Advocate Foundation (PAF) and provides emergency food delivery and financial assistance to people living with cancer, multiple sclerosis, and rheumatoid arthritis.

      Who is Eligible?

      Patients with cancer, multiple sclerosis or rheumatoid arthritis who have trouble accessing or affording food or other nutritional needs due to COVID-19, with eligibility established at the point of application in most cases.

      For more information, including application instructions, click here.  

      Posted 7/2/2020



    • FDA Approves Pembrolizumab for First-line Treatment of Metastatic MSI-H or dMMR CRC

      On June 29, 2020, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co.) for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

      Read FDA announcement.

      Posted 6/30/2020



    • Live Discussion: CD38-Directed Antibody for the Treatment of RRMM

      CD38-Directed Antibody for the Treatment of Appropriate Relapsed Refractory Multiple Myeloma Patients
       
      Thursday, June 25
      5:00 PM PT

      Participants of this live discussion will be able to:

      • Learn about the indication, mechanism of action, and important safety information for Sarclisa (isatuximab-irfc)

      • Gain in-depth knowledge on clinical data in adult patients with relapsed refractory multiple myeloma

      • Understand the dosage and administration of Sarclisa.

      • Learn about support available for eligible patients treated with Sarclisa. 

      For registration information or to learn more, click here

      Posted 6/25/2020




    1801 Research Boulevard Suite 400
    Rockville, MD 20850
    Tel: 301.984.9496 | Fax: 301.770.1949
    laoncologysociety.org
    Email Us